Pavmed Inc (PAVM)

Feb 20, 2025, 8:31 AM EST - 2 days ago

Lucid Diagnostics Executes First Concierge Medicine Contract with LEAA Health

LUCD

Feb 18, 2025, 8:30 AM EST - 4 days ago

PAVmed Regains Compliance with Nasdaq Stockholders' Equity Requirement

LUCD

Feb 6, 2025, 8:57 AM EST - 16 days ago

Lucid Diagnostics to Participate in the 12th Annual BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

LUCD

Jan 13, 2025, 7:56 AM EST - 5 weeks ago

Lucid Diagnostics Announces Record Quarterly EsoGuard® Test Volume

LUCD

Dec 23, 2024, 8:01 AM EST - 2 months ago

Lucid Diagnostics Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule

LUCD

Dec 19, 2024, 8:01 AM EST - 2 months ago

Lucid Diagnostics Partners with VITALExam to Enhance Esophageal Precancer Detection for Firefighters

LUCD

Dec 11, 2024, 8:01 AM EST - 2 months ago

Prospective Clinical Utility Study of Lucid Diagnostics' EsoGuard® Esophageal DNA Test Accepted for Peer-Reviewed Publication

LUCD

Dec 3, 2024, 8:01 AM EST - 2 months ago

Lucid Diagnostics Completes Convertible Debt Refinancing to Strengthen Balance Sheet and Extend Cash Runway Past Key Near-Term Milestones

LUCD

Nov 20, 2024, 7:56 AM EST - 3 months ago

Lucid Diagnostics Submits Clinical Evidence Package to MolDX Seeking Medicare Coverage for EsoGuard® Esophageal DNA Test

LUCD

Nov 18, 2024, 8:15 AM EST - 3 months ago

Lucid Diagnostics to Present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum

LUCD

Nov 14, 2024, 3:49 PM EST - 3 months ago

PAVmed Inc. (PAVM) Q3 2024 Earnings Call Transcript

Nov 14, 2024, 8:01 AM EST - 3 months ago

PAVmed Provides Business Update and Third Quarter 2024 Financial Results

Nov 13, 2024, 8:01 AM EST - 3 months ago

Lucid Diagnostics Provides Business Update and Third Quarter 2024 Financial Results

LUCD

Nov 7, 2024, 8:01 AM EST - 3 months ago

Lucid Diagnostics' ESOGUARD BE-1 Prospective Multicenter Clinical Validation Study of EsoGuard® Esophageal Precancer Testing Accepted for Peer-Reviewed Publication

LUCD

Nov 5, 2024, 8:01 AM EST - 3 months ago

Lucid Diagnostics Expands Direct Contracting Initiative with Multiple Programs Focused on Near-Term Revenue Drivers

LUCD

Oct 31, 2024, 8:31 AM EDT - 4 months ago

PAVmed to Hold a Business Update Conference Call and Webcast on November 14, 2024

Oct 30, 2024, 8:31 AM EDT - 4 months ago

Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on November 13, 2024

LUCD

Oct 15, 2024, 7:51 AM EDT - 4 months ago

Lucid Diagnostics Receives Notice of Allowance for Key Patent Underlying Its EsoGuard Esophageal DNA Test

LUCD

Oct 10, 2024, 7:51 AM EDT - 4 months ago

PAVmed Subsidiary, Veris Health, Awarded $1.8 Million NIH Grant to Enhance Cancer Care

Oct 9, 2024, 8:01 AM EDT - 4 months ago

Lucid Diagnostics to Participate in the 2024 Maxim Healthcare Virtual Summit

LUCD

Oct 8, 2024, 7:49 AM EDT - 4 months ago

Lucid Diagnostics to Join Global Medtech Leaders at The MedTech Conference 2024

LUCD

Sep 24, 2024, 8:01 AM EDT - 5 months ago

American Foregut Society's 2024 Annual Meeting to Highlight Lucid Diagnostics' EsoGuard Esophageal Precancer Test

LUCD

Sep 16, 2024, 4:30 PM EDT - 5 months ago

PAVmed Announces Efforts to Regain Compliance with Nasdaq Listing Requirements

LUCD

Sep 10, 2024, 7:56 AM EDT - 5 months ago

Lucid Diagnostics to Host Symposium on Non-Endoscopic Esophageal Precancer Screening at the 20th International Society for Diseases of the Esophagus (ISDE) World Congress

LUCD

Sep 3, 2024, 7:51 AM EDT - 6 months ago

Lucid Diagnostics Signs Memorandum of Understanding with Front Line Mobile Health

LUCD

Aug 20, 2024, 8:16 AM EDT - 6 months ago

Lucid Diagnostics Announces Publication of Analytical Validation Study of EsoGuard® for Early Detection of Esophageal Precancer and Cancer

LUCD

Aug 13, 2024, 6:59 PM EDT - 6 months ago

PAVmed Inc. (PAVM) Q2 2024 Earnings Call Transcript

Aug 13, 2024, 8:16 AM EDT - 6 months ago

The American Foregut Society Formally Requests Medical Policy Coverage of EsoGuard® to Enhance Early Detection of Esophageal Cancer

LUCD

Aug 13, 2024, 8:01 AM EDT - 6 months ago

PAVmed Provides Business Update and Second Quarter 2024 Financial Results

LUCD

Aug 12, 2024, 8:07 AM EDT - 6 months ago

Lucid Diagnostics Provides Business Update and Second Quarter 2024 Financial Results

LUCD

Aug 8, 2024, 8:31 AM EDT - 7 months ago

Lucid Diagnostics Holds First Major Directly-Contracted EsoGuard® #CheckYourFoodTube Precancer Testing Event

LUCD

Aug 6, 2024, 8:15 AM EDT - 7 months ago

Lucid Diagnostics Announces Positive Data from ENVET-BE Clinical Utility Study of EsoGuard® Esophageal Precancer Testing

LUCD

Aug 5, 2024, 8:15 AM EDT - 7 months ago

Lucid Diagnostics to Participate in Upcoming Investor Conferences

LUCD

Jul 30, 2024, 8:15 AM EDT - 7 months ago

PAVmed to Hold a Business Update Conference Call and Webcast on August 13, 2024

Jul 29, 2024, 8:15 AM EDT - 7 months ago

Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on August 12, 2024

LUCD

Jul 11, 2024, 8:31 AM EDT - 8 months ago

Lucid Diagnostics Launches New Corporate Website

LUCD

Jul 2, 2024, 7:55 AM EDT - 8 months ago

Lucid Diagnostics Announces Positive Data from its ESOGUARD BE-1 Prospective, International, Multicenter Clinical Validation Study of EsoGuard® Esophageal Precancer Testing in a Screening Population

LUCD

Jun 13, 2024, 7:58 AM EDT - 9 months ago

PAVmed Subsidiary, Veris Health, Announces Launch of Pilot Program with The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute

Jun 12, 2024, 8:05 AM EDT - 9 months ago

4,000th Firefighter Undergoes Lucid Diagnostics' EsoGuard® Esophageal Precancer Testing

LUCD

May 14, 2024, 11:59 AM EDT - 10 months ago

PAVmed Inc. (PAVM) Q1 2024 Earnings Call Transcript

May 13, 2024, 8:43 PM EDT - 10 months ago

PAVmed Provides Business Update and First Quarter 2024 Financial Results

LUCD

May 13, 2024, 8:00 AM EDT - 10 months ago

Lucid Diagnostics Provides Business Update and First Quarter 2024 Financial Results

LUCD

May 9, 2024, 7:49 AM EDT - 10 months ago

Legacy Sponge-on-a-String Esophageal Cell Collection Device Subject of Class II FDA Recall

LUCD

May 7, 2024, 7:39 AM EDT - 10 months ago

Lucid Diagnostics Closes Series B / B-1 Preferred Stock Offering and Appoints Healthcare Industry Veteran Dennis Matheis to Board of Directors

LUCD

May 3, 2024, 8:35 AM EDT - 10 months ago

PAVmed to Hold a Business Update Conference Call and Webcast on May 14, 2024

May 2, 2024, 7:49 AM EDT - 10 months ago

Lucid Diagnostics Announces Peer-Reviewed Publication of Positive Data from National Cancer Institute-Sponsored, Prospective, Multicenter Clinical Validation Study of EsoGuard® Esophageal Precancer Testing

LUCD

Apr 30, 2024, 7:35 AM EDT - 10 months ago

PAVmed Subsidiary, Veris Health, Signs Memorandum of Understanding with The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute

Apr 29, 2024, 8:47 AM EDT - 10 months ago

Lucid Diagnostics Partners with the Esophageal Cancer Action Network (ECAN) to Highlight Esophageal Cancer Awareness Month

LUCD

Apr 8, 2024, 8:30 AM EDT - 11 months ago

Lucid Diagnostics to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference

LUCD

Mar 27, 2024, 3:12 PM EDT - 11 months ago

PAVmed Inc. (PAVM) Q4 2023 Earnings Call Transcript